- Home
- KTOS vs MRNA Comparison
KTOS vs MRNA Comparison
Compare KTOS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KTOS | MRNA |
|---|---|---|
| Founded | 1994 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 11.5B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KTOS | MRNA |
|---|---|---|
| Price | $87.55 | $52.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 17 | 12 |
| Target Price | ★ $97.44 | $33.00 |
| AVG Volume (30 Days) | 4.0M | ★ 9.0M |
| Earning Date | 05-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 21.77 |
| EPS | ★ 0.13 | N/A |
| Revenue | $751,900,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $24.96 | $8.28 |
| Revenue Next Year | $23.89 | $16.53 |
| P/E Ratio | $688.04 | ★ N/A |
| Revenue Growth | ★ 12.44 | 4.29 |
| 52 Week Low | $27.51 | $22.28 |
| 52 Week High | $134.00 | $59.55 |
Technical Indicators
Market Signals| Indicator | KTOS | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 54.70 |
| Support Level | $82.27 | $48.09 |
| Resistance Level | $95.85 | $55.20 |
| Average True Range (ATR) | 5.86 | 3.56 |
| MACD | 0.12 | -0.30 |
| Stochastic Oscillator | 38.59 | 33.94 |
Price Performance
Historical ComparisonAbout KTOS Kratos Defense & Security Solutions Inc.
Kratos Defense & Security Solutions Inc develops and fields transformative, affordable technology, platforms, and systems. The company has two segments; The Kratos Government Solutions (KGS) segment is comprised of an aggregation of KGS operating segments, including its microwave electronic products, space, training, and cybersecurity, C5ISR/modular systems, turbine technologies, and defense and rocket support services operating segments and The Unmanned Systems segment consists of unmanned aerial, unmanned ground, unmanned seaborne and related command, control, and communications system businesses. The company derives a majority of its revenue from the Kratos Government Solutions segment.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.